Amibegron

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Amibegron
Amibegron.png
Systematic (IUPAC) name
Ethyl ([(7S)-7-([(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy)acetate
Clinical data
Legal status ?
Identifiers
CAS number 121524-09-2
ATC code None
PubChem CID 3035442
IUPHAR ligand 568
ChemSpider 108738 YesY
UNII PDQ3ME68U3 YesY
KEGG D08851 YesY
ChEMBL CHEMBL545437 YesY
Chemical data
Formula C22H26ClNO4 
Mol. mass 403.898 g/mol
 YesY (what is this?)  (verify)

Amibegron (SR-58,611A) is a drug developed by Sanofi-Aventis which acts as a selective agonist for the β3 adrenergic receptor. It is the first orally active β3 agonist developed that is capable of entering the Central Nervous System, and has antidepressant and anxiolytic effects.12

On July 31, 2008, Sanofi-Aventis announced that it has decided to discontinue development of amibegron.3

References

  1. ^ Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Santucci V, Françon D, Alonso R, Stahl SM, Keane P, Avenet P, Scatton B, le Fur G, Griebel G. Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology. 2008 Feb;33(3):574-87. PMID 17460614
  2. ^ Overstreet DH, Stemmelin J, Griebel G. Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression. Pharmacology, Biochemistry and Behaviour. 2008 Jun;89(4):623-6. doi:10.1016/j.pbb.2008.02.020 PMID 18358519
  3. ^ Second quarter 2008 results. July 31, 2008, retrieved March 9, 2009.